Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.6K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.6K
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.7K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

7.2K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
7.2K
Phase I Reactions: Reductive Reactions01:27

Phase I Reactions: Reductive Reactions

801
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
801
Analgesia and Pain Management01:25

Analgesia and Pain Management

3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Low-Dose Naltrexone: What is the Evidence? A Narrative Review.

Advances in therapy·2026
Same author

Tobacco, nicotine, and cannabis use and exposure in an Australian Indigenous population during pregnancy: A protocol to measure parental and foetal exposure and outcomes.

PloS one·2024
Same author

Medication Lubricants for Oral Delivery of Drugs: Oral Processing Reduces Thickness, Changes Characteristics, and Improves Dissolution Profile.

Pharmaceutics·2024
Same author

Deprescribing Tool for Older PeoPle with Limited-life Expectancy (De-TOPPLE) version 1: Development and validation using a modified Delphi technique.

Basic & clinical pharmacology & toxicology·2023
Same author

Health literacy in Pakistani migrants in Australia-An emerging and neglected culturally and linguistically diverse community.

Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals·2023
Same author

Perceived Usability of Tablet Crushers: Comparison of Devices by People with and without Limited Hand Functions.

Pharmaceutics·2023

Related Experiment Video

Updated: May 1, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
07:50

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

9.4K

Low-Dose Naltrexone: What is the Evidence? A Narrative Review.

Amina H K Gouda1, Nicholas E C Aitcheson2, Kathryn J Steadman3

  • 1School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD, 4102, Australia. a.gouda@uq.edu.au.

Advances in Therapy
|April 30, 2026
PubMed
Summary

Low-dose naltrexone (LDN) shows promise but lacks robust evidence for widespread use. While generally safe and inexpensive, larger trials are needed to confirm its clinical value, especially for treatment-resistant conditions.

Keywords:
FibromyalgiaOff-label prescribingOpioid receptor antagonistPain management

More Related Videos

A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

6.8K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

1.8K

Related Experiment Videos

Last Updated: May 1, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
07:50

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training

Published on: January 29, 2017

9.4K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

6.8K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

1.8K

Area of Science:

  • Pharmacology and Therapeutics
  • Evidence-Based Medicine
  • Clinical Research

Background:

  • Low-dose naltrexone (LDN) is used off-label for various conditions at doses typically between 0.5-6.0 mg.
  • The clinical evidence supporting LDN's efficacy across diverse therapeutic areas requires thorough evaluation.

Purpose of the Study:

  • To systematically review the existing clinical evidence for low-dose naltrexone (LDN).
  • To assess the quality and consistency of findings from studies investigating LDN across multiple medical fields.

Main Methods:

  • A comprehensive literature search was performed in February 2026 across PubMed, Embase, and CINAHL for studies from 1989 to 2026.
  • 105 studies, including 15 randomized controlled trials (RCTs), were reviewed, focusing on doses ≤ 12.5 mg in humans for conditions like chronic pain, autoimmune disorders, and mental health.
  • Studies were analyzed for findings in chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious syndromes, mental health, and oncology.

Main Results:

  • Early positive findings from uncontrolled studies were infrequently replicated in placebo-controlled trials.
  • The majority of evidence comprises case reports and small feasibility studies, often relying on subjective outcomes and susceptible to publication bias.
  • LDN is generally safe, inexpensive, and well-tolerated, with 4.5 mg being a common daily dose.

Conclusions:

  • Current evidence does not support the routine clinical use of LDN.
  • LDN may offer a pragmatic option for treatment-resistant cases after standard therapies fail, but its experimental nature and uncertain efficacy must be communicated.
  • Larger, well-designed RCTs with objective endpoints and N-of-1 studies are necessary to determine LDN's true clinical value and identify potential responders.